Lauro Fabián Amador Medina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lauro Fabián Amador Medina has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Alejandra Álvarez Salinas
Anesthesiology, Universidad de Guanajuato, León, MEX
2 shared publications- Eréndira Pacheco Zavala
Hematology Service, Hematology‐Oncology Department, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 1, Centro Médico Nacional Del Bajío, IMSS, León Guanajuato México
2 shared publications Marcos Javier Romero Vázquez
Department of Medicine and Nutrition, University of Guanajuato, Leon Guanajuato, Mexico
2 shared publicationsOctavio Martínez Villegas
High Specialty Medical Unit, Hospital of Gynecology and Pediatrics No. 48, Mexican Institute of Social Security, Leon, Guanajuato, Mexico
2 shared publications- Octavio Martínez-Villegas
Unidad Médica de Alta Especialidad, Hospital de Gineco-Pediatría No. 48, Centro Médico Nacional del Bajío, León 37328, Mexico
2 shared publications - Adriana Aguilar-Lemarroy
Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico
1 shared publication
Latest Publications
- Open Access
- 18 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Primary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma that most commonly presents with nodal disease, while primary involvement of the central nervous system (CNS) is rare, particularly in immunocompetent patients. We describe the case of a 41-year-old immunocompetent male who presented with progressive left-sided hemiparesis, ipsilateral facial palsy, severe headache, and decreased level of consciousness. Neuroimaging findings and histopathological examination confirmed the diagnosis of primary CNS DLBCL. Subsequent systemic evaluation with PET-CT revealed increased metabolic activity in the testicular and prostatic regions, consistent with secondary extranodal involvement. The patient was treated with a MATRIX-based chemotherapy regimen, including high-dose methotrexate, cytarabine, and rituximab, in accordance with current guidelines for primary CNS lymphoma. This case highlights an unusual presentation of primary CNS DLBCL with early systemic dissemination to testicular and prostatic tissue, underscoring the importance of comprehensive staging and prompt initiation of high-dose methotrexate-based therapy to optimize clinical outcomes.
- 18 January 2026
- Published by Springer Nature in Cureus
- Vol. 18 (1)
Open AccessPrimary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma that most commonly presents with nodal disease, while primary involvement of the central nervous system (CNS) is rare, particularly in immunocompetent patients. We describe the case of a 41-year-old immunocompetent male who presented with progressive left-sided hemiparesis, ipsilateral facial palsy, severe headache, and decreased level of consciousness. Neuroimaging findings and histopathological examination confirmed the diagnosis of primary CNS DLBCL. Subsequent systemic evaluation with PET-CT revealed increased metabolic activity in the testicular and prostatic regions, consistent with secondary extranodal involvement. The patient was treated with a MATRIX-based chemotherapy regimen, including high-dose methotrexate, cytarabine, and rituximab, in accordance with current guidelines for primary CNS lymphoma. This case highlights an unusual presentation of primary CNS DLBCL with early systemic dissemination to testicular and prostatic tissue, underscoring the importance of comprehensive staging and prompt initiation of high-dose methotrexate-based therapy to optimize clinical outcomes.
- Open Access
- 9 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 674
Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a genetically heterogeneous disease where current clinical practice guidelines remain focused on traditional cytogenetic markers. Despite recent advances demonstrating excellent diagnostic accuracy for gene expression signatures, a discontinuity exists between biomarker validation and clinical implementation. This study aimed to develop and validate a multiparametric gene expression signature using digital PCR (dPCR) to accurately diagnose pediatric ALL, with potential utility for monitoring measurable residual disease (MRD). We analyzed 130 bone marrow aspirates from pediatric patients from four clinical groups: non-leukemia, MRD-negative, MRD-positive and leukemia characterized by immunophenotype. Gene expression of an 8-gene panel (JUP, MYC, NT5C3B, GATA3, PTK7, CNP, ICOSLG, and SNAI1) was quantified by dPCR. The diagnostic performance of individual markers was assessed, and a Random Forest machine learning model was trained to classify active disease. The model was validated using a 5-fold stratified cross-validation approach. Individual markers, particularly JUP, MYC, and NT5C3B, showed good diagnostic accuracy for distinguishing leukemia from non-leukemia. However, integrating all eight markers into a multivariate Random Forest model significantly enhanced performance. The model achieved a mean cross-validated area under the curve (AUC) of 0.908 (±0.041) on receiver operator characteristic (ROC) analysis and 0.961 (±0.019) on Precision–Recall (PR) analysis, demonstrating high reliability and a favorable balance between sensitivity and precision. The integrated model achieved high sensitivity (88.9%) for detecting active disease, particularly at initial diagnosis. Although specificity was moderate (65.0%), the high positive predictive value (PPV 85.1%) and accuracy (81.5%) confirm the clinical utility of a positive result. While the panel showed promising performance for distinguishing MRD-positive from MRD-negative samples, the limited MRD-positive cohort size (n = 11) indicates that validation in larger MRD-focused studies is required before clinical implementation for treatment monitoring. This dPCR-based platform provides accessible, quantitative detection without requiring knowledge of clonal shifts or specific genomic landscape, offering potential advantages for resource-limited settings such as those represented in our Mexican pediatric cohort.
- 9 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 674
Open AccessUtility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a genetically heterogeneous disease where current clinical practice guidelines remain focused on traditional cytogenetic markers. Despite recent advances demonstrating excellent diagnostic accuracy for gene expression signatures, a discontinuity exists between biomarker validation and clinical implementation. This study aimed to develop and validate a multiparametric gene expression signature using digital PCR (dPCR) to accurately diagnose pediatric ALL, with potential utility for monitoring measurable residual disease (MRD). We analyzed 130 bone marrow aspirates from pediatric patients from four clinical groups: non-leukemia, MRD-negative, MRD-positive and leukemia characterized by immunophenotype. Gene expression of an 8-gene panel (JUP, MYC, NT5C3B, GATA3, PTK7, CNP, ICOSLG, and SNAI1) was quantified by dPCR. The diagnostic performance of individual markers was assessed, and a Random Forest machine learning model was trained to classify active disease. The model was validated using a 5-fold stratified cross-validation approach. Individual markers, particularly JUP, MYC, and NT5C3B, showed good diagnostic accuracy for distinguishing leukemia from non-leukemia. However, integrating all eight markers into a multivariate Random Forest model significantly enhanced performance. The model achieved a mean cross-validated area under the curve (AUC) of 0.908 (±0.041) on receiver operator characteristic (ROC) analysis and 0.961 (±0.019) on Precision–Recall (PR) analysis, demonstrating high reliability and a favorable balance between sensitivity and precision. The integrated model achieved high sensitivity (88.9%) for detecting active disease, particularly at initial diagnosis. Although specificity was moderate (65.0%), the high positive predictive value (PPV 85.1%) and accuracy (81.5%) confirm the clinical utility of a positive result. While the panel showed promising performance for distinguishing MRD-positive from MRD-negative samples, the limited MRD-positive cohort size (n = 11) indicates that validation in larger MRD-focused studies is required before clinical implementation for treatment monitoring. This dPCR-based platform provides accessible, quantitative detection without requiring knowledge of clonal shifts or specific genomic landscape, offering potential advantages for resource-limited settings such as those represented in our Mexican pediatric cohort.
- Open Access
- 16 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Severe Octreotide-Induced Immune Thrombocytopenia With Bone Marrow Findings Suggestive of Acquired Amegakaryocytic Thrombocytopenic Purpura in a Cirrhotic Woman: An Unusual Case Report
Drug-induced immune thrombocytopenia (DIT) is a rare but potentially life-threatening condition that is often underrecognized in clinical practice. Octreotide, a somatostatin analogue used to control GI bleeding, has rarely been associated with DIT. We describe an 80-year-old woman with metabolic cirrhosis and chronic thrombocytopenia who developed profound thrombocytopenia and severe bleeding shortly after initiating octreotide. Bone marrow evaluation revealed marked megakaryocytic hypoplasia, initially suggestive of acquired amegakaryocytic thrombocytopenic purpura (AATP). Antiplatelet antibodies were detected, and the patient responded rapidly to dexamethasone, intravenous immunoglobulin, and eltrombopag. Although the presentation resembled classic DIT, the marrow findings and clinical course suggested overlapping features of AATP and bone marrow aplasia. This case underscores the diagnostic challenges of thrombocytopenia in cirrhosis, the potential suppressive effect of octreotide on megakaryopoiesis, and the importance of early marrow assessment and immunosuppressive therapy in severe cases.
- 16 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Open AccessSevere Octreotide-Induced Immune Thrombocytopenia With Bone Marrow Findings Suggestive of Acquired Amegakaryocytic Thrombocytopenic Purpura in a Cirrhotic Woman: An Unusual Case Report
Drug-induced immune thrombocytopenia (DIT) is a rare but potentially life-threatening condition that is often underrecognized in clinical practice. Octreotide, a somatostatin analogue used to control GI bleeding, has rarely been associated with DIT. We describe an 80-year-old woman with metabolic cirrhosis and chronic thrombocytopenia who developed profound thrombocytopenia and severe bleeding shortly after initiating octreotide. Bone marrow evaluation revealed marked megakaryocytic hypoplasia, initially suggestive of acquired amegakaryocytic thrombocytopenic purpura (AATP). Antiplatelet antibodies were detected, and the patient responded rapidly to dexamethasone, intravenous immunoglobulin, and eltrombopag. Although the presentation resembled classic DIT, the marrow findings and clinical course suggested overlapping features of AATP and bone marrow aplasia. This case underscores the diagnostic challenges of thrombocytopenia in cirrhosis, the potential suppressive effect of octreotide on megakaryopoiesis, and the importance of early marrow assessment and immunosuppressive therapy in severe cases.
- 22 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 6050-6054
Dapagliflozin prevents glucocorticoid‐induced hyperglycaemia: Results from the DAPACOID Phase II Clinical Trial
- 22 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 6050-6054
Dapagliflozin prevents glucocorticoid‐induced hyperglycaemia: Results from the DAPACOID Phase II Clinical Trial
- 8 March 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (2) , 507-511
Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels
In adults with severe hemophilia A, a streamlined approach to pharmacokinetic (PK) studies, which involves fewer Factor VIII determinations and emphasizes the time needed to achieve specific trough levels, presents an appealing option. To determine the PK profile of Factor VIII using a single measurement taken 24 h after a standard prophylactic regimen. Based on these findings, personalized prophylactic recommendations were established. The study included adults with severe hemophilia A undergoing standard prophylaxis without inhibitors. A single determination of Factor VIII was performed 24 h after the usual administration of the concentrate. PK analysis was conducted using the digital tool WAPPS-Hemo. Key parameters analyzed included maximum concentration (Cmax), area under the curve (AUC), half-life (t½), clearance (Cl), volume of distribution (Vd), trough levels, and the need for dose adjustments. A total of 25 patients were enrolled in the study. The median times to reach trough levels of 5, 2, and 1% were 33, 51, and 59 h, respectively. The median values for Cmax, AUC, t½, Cl, and Vd were 0.70 IU/mL, 7170 mg·h/L, 10 h, 0.37 L/h, and 33 L/kg, respectively. The median Factor VIII level at 24 h was 0.07 IU/mL. Dose adjustments were required for 72% of patients to maintain a 5% trough level, 40% for a 2% trough level, and 36% for a 1% trough level. This approach supports personalized prophylaxis in adults with severe hemophilia A by targeting specific trough levels.
- 8 March 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (2) , 507-511
Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels
In adults with severe hemophilia A, a streamlined approach to pharmacokinetic (PK) studies, which involves fewer Factor VIII determinations and emphasizes the time needed to achieve specific trough levels, presents an appealing option. To determine the PK profile of Factor VIII using a single measurement taken 24 h after a standard prophylactic regimen. Based on these findings, personalized prophylactic recommendations were established. The study included adults with severe hemophilia A undergoing standard prophylaxis without inhibitors. A single determination of Factor VIII was performed 24 h after the usual administration of the concentrate. PK analysis was conducted using the digital tool WAPPS-Hemo. Key parameters analyzed included maximum concentration (Cmax), area under the curve (AUC), half-life (t½), clearance (Cl), volume of distribution (Vd), trough levels, and the need for dose adjustments. A total of 25 patients were enrolled in the study. The median times to reach trough levels of 5, 2, and 1% were 33, 51, and 59 h, respectively. The median values for Cmax, AUC, t½, Cl, and Vd were 0.70 IU/mL, 7170 mg·h/L, 10 h, 0.37 L/h, and 33 L/kg, respectively. The median Factor VIII level at 24 h was 0.07 IU/mL. Dose adjustments were required for 72% of patients to maintain a 5% trough level, 40% for a 2% trough level, and 36% for a 1% trough level. This approach supports personalized prophylaxis in adults with severe hemophilia A by targeting specific trough levels.
- Open Access
- 3 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3)
Antineutrophil Cytoplasmic Antibodies-Associated Glomerulonephritis in Diabetic Kidney Disease
Diabetic kidney disease is a very prevalent complication in the context of type 2 diabetes. However, there is evidence showing a high variability in diagnosis when a kidney biopsy is performed. We present a case of a woman with a diagnosis of diabetic kidney disease, systemic arterial hypertension, obesity, and a high risk of progression of chronic kidney disease who presented with a sudden onset nephrotic syndrome and rapidly progressive deterioration of renal function. Kidney biopsy revealed pauci-immune extracapillary glomerulonephritis with acute thrombotic microangiopathy and class IIa diabetic nephropathy. Antineutrophil cytoplasmic antibodies (ANCA) and low complement were detected. The patient received treatment based on plasma exchanges, steroids with methylprednisolone and prednisone and intravenous cyclophosphamide with improvement of renal function. In conclusion, expansion of kidney biopsy criteria in patients with a diagnosis of type 2 diabetes is mandatory to provide adequate treatment and prognosis in the context of a high prevalence of alternative or concomitant disease.
- 3 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3)
Open AccessAntineutrophil Cytoplasmic Antibodies-Associated Glomerulonephritis in Diabetic Kidney Disease
Diabetic kidney disease is a very prevalent complication in the context of type 2 diabetes. However, there is evidence showing a high variability in diagnosis when a kidney biopsy is performed. We present a case of a woman with a diagnosis of diabetic kidney disease, systemic arterial hypertension, obesity, and a high risk of progression of chronic kidney disease who presented with a sudden onset nephrotic syndrome and rapidly progressive deterioration of renal function. Kidney biopsy revealed pauci-immune extracapillary glomerulonephritis with acute thrombotic microangiopathy and class IIa diabetic nephropathy. Antineutrophil cytoplasmic antibodies (ANCA) and low complement were detected. The patient received treatment based on plasma exchanges, steroids with methylprednisolone and prednisone and intravenous cyclophosphamide with improvement of renal function. In conclusion, expansion of kidney biopsy criteria in patients with a diagnosis of type 2 diabetes is mandatory to provide adequate treatment and prognosis in the context of a high prevalence of alternative or concomitant disease.
- 17 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 93-99
Efficacy of Brentuximab-Vedotin Combined with PD-1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma with ASCT Consolidation and Maintenance Therapy: A Phase 2 Clinical Trial
Approximately 30% of patients with Hodgkin lymphoma experience relapse or are refractory to first-line chemotherapy. For these patients, immunotherapy has emerged as an effective option. Current treatments include anti-CD30 (Brentuximab-Vedotin) and PD-1 inhibitors (Nivolumab or Pembrolizumab), often in combination with Autologous Stem Cell Transplantation (ASCT). This study aims to evaluate clinical outcomes in a cohort of patients with relapsed/refractory Hodgkin lymphoma (R/R HL) undergoing treatment with immunotherapy combined with ASCT. This is an open-label, single-arm clinical trial involving patients diagnosed with R/R HL who were treated with Brentuximab-Vedotin (BV) combined with a PD-1 inhibitor, followed by consolidation with ASCT and maintenance therapy using BV and a PD-1 inhibitor. An intention-to-treat analysis was performed. The primary endpoints were complete remission rate (CRR), progression-free survival (PFS), overall survival (OS), and the occurrence of severe adverse events. Fifteen patients were included in the study (8 men and 7 women). The median age was 27 years, with an interquartile range (IQR) of 23–37 years. The median follow-up period for the entire cohort was 41.3 months. The pre-transplant CRR was 80%, and the PFS was also 80%. OS at the last follow-up was 100%. No severe adverse events were observed. ASCT was performed in 60% of the patients. This treatment strategy demonstrates high OS and PFS with no serious adverse effects, suggesting that it could be a clinically beneficial approach for patients with R/R HL. Further studies are needed to validate these findings in larger cohorts. The study is registered at ClinicalTrials.gov under the identifier NCT05595447.
- 17 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 93-99
Efficacy of Brentuximab-Vedotin Combined with PD-1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma with ASCT Consolidation and Maintenance Therapy: A Phase 2 Clinical Trial
Approximately 30% of patients with Hodgkin lymphoma experience relapse or are refractory to first-line chemotherapy. For these patients, immunotherapy has emerged as an effective option. Current treatments include anti-CD30 (Brentuximab-Vedotin) and PD-1 inhibitors (Nivolumab or Pembrolizumab), often in combination with Autologous Stem Cell Transplantation (ASCT). This study aims to evaluate clinical outcomes in a cohort of patients with relapsed/refractory Hodgkin lymphoma (R/R HL) undergoing treatment with immunotherapy combined with ASCT. This is an open-label, single-arm clinical trial involving patients diagnosed with R/R HL who were treated with Brentuximab-Vedotin (BV) combined with a PD-1 inhibitor, followed by consolidation with ASCT and maintenance therapy using BV and a PD-1 inhibitor. An intention-to-treat analysis was performed. The primary endpoints were complete remission rate (CRR), progression-free survival (PFS), overall survival (OS), and the occurrence of severe adverse events. Fifteen patients were included in the study (8 men and 7 women). The median age was 27 years, with an interquartile range (IQR) of 23–37 years. The median follow-up period for the entire cohort was 41.3 months. The pre-transplant CRR was 80%, and the PFS was also 80%. OS at the last follow-up was 100%. No severe adverse events were observed. ASCT was performed in 60% of the patients. This treatment strategy demonstrates high OS and PFS with no serious adverse effects, suggesting that it could be a clinically beneficial approach for patients with R/R HL. Further studies are needed to validate these findings in larger cohorts. The study is registered at ClinicalTrials.gov under the identifier NCT05595447.
- Open Access
- 23 September 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S322-S331
Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
- 23 September 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S322-S331
Open AccessVenetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
- 18 May 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 60-68
Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, and the Hispanic race has the highest incidence worldwide. Disparities in survival rates exist among different regions of the world. Due to this heterogeneity and possible differences in the outcomes within Mexico, the aim of this study was to analyze the clinical outcomes of cohort of pediatric patients with ALL treated in a highly specialized medical unit located in the Bajio region of Mexico. Observational retrospective study of a cohort of pediatric patients with ALL treated in a tertiary-level hospital in the Bajio region of Mexico, between January 2016 and December 2021. A total of 146 patients were included with a median age of 7 years. The 68.5% of patients were at high risk. CNS involvement was present in 2.7%, and Philadelphia chromosome positive in 2%. Cytogenetic analysis was performed in 16.4% patients. The median follow-up of entire cohort was 32 months. The most frequently administered chemotherapy treatment was Total Therapy XV in 79.5% of patients. The complete remission rate was 89%. Refractory disease was present in 2.7%. Induction-related mortality was 8.2%. The relapse rate was present in 26%. The 3-years overall survival was 57.5%, and the 3-years event-free survival was 53.4%. A more aggressive course and worse survival occur in our cohort of pediatric patients with ALL. Strategies should be proposed inside Mexico and other low-middle income countries with the aim of improving the overall survival.
- 18 May 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 60-68
Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, and the Hispanic race has the highest incidence worldwide. Disparities in survival rates exist among different regions of the world. Due to this heterogeneity and possible differences in the outcomes within Mexico, the aim of this study was to analyze the clinical outcomes of cohort of pediatric patients with ALL treated in a highly specialized medical unit located in the Bajio region of Mexico. Observational retrospective study of a cohort of pediatric patients with ALL treated in a tertiary-level hospital in the Bajio region of Mexico, between January 2016 and December 2021. A total of 146 patients were included with a median age of 7 years. The 68.5% of patients were at high risk. CNS involvement was present in 2.7%, and Philadelphia chromosome positive in 2%. Cytogenetic analysis was performed in 16.4% patients. The median follow-up of entire cohort was 32 months. The most frequently administered chemotherapy treatment was Total Therapy XV in 79.5% of patients. The complete remission rate was 89%. Refractory disease was present in 2.7%. Induction-related mortality was 8.2%. The relapse rate was present in 26%. The 3-years overall survival was 57.5%, and the 3-years event-free survival was 53.4%. A more aggressive course and worse survival occur in our cohort of pediatric patients with ALL. Strategies should be proposed inside Mexico and other low-middle income countries with the aim of improving the overall survival.
- 15 January 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 487-493
Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study
Congenital Hemophilia A is a complex disease to treat, especially in places without access to hemophilia treatment centers (HTCs). The primary aim of this study was to analyze the outcomes of a cohort of adult people with congenital hemophilia A in an HTC localized in the Bajio region of Mexico. Observational retrospective study of a cohort of 82 adult people with congenital hemophilia A treated in a tertiary-level hospital in the Bajio region of Mexico, between June 2022 and June 2023. The median age of the patients was 29.5 years, 60.9% with severe hemophilia A, 53.6% were under some factor VIII prophylaxis regimen, and 52.4% had home therapy. The median annualized bleeding rate (ABR) was one bleed/year (IQR 0–3 bleeds/year) including a median of zero joint bleeds/year (IQR 0–3 bleeds/year). The presence of high-response inhibitors was detected in 8.5%, with an overall incidence of inhibitors of 14.6% of the cohort. Univariate analysis showed that inhibitors (OR 21.10; CI 95% 1.20–370.3; P = 0.03) and clinical arthropathy (OR 6.14; CI 95% 2.13–17.68; P = 0.001) were significantly higher in severe hemophilia. Clinically significant arthropathy was found in 71.9% of patients. Ultrasonography of the target joints showed that mainly cartilage degeneration was affected. Blood transfusion-associated viral infections were detected in 10.9% of patients. In our HTC, current treatment with hemostatic agents allows adequate control of ABR with acceptable inhibitor rates. However, we still have joint damage in most patients, which is partly explained by the fact that prophylaxis was introduced only in recent years.
- 15 January 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 487-493
Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study
Congenital Hemophilia A is a complex disease to treat, especially in places without access to hemophilia treatment centers (HTCs). The primary aim of this study was to analyze the outcomes of a cohort of adult people with congenital hemophilia A in an HTC localized in the Bajio region of Mexico. Observational retrospective study of a cohort of 82 adult people with congenital hemophilia A treated in a tertiary-level hospital in the Bajio region of Mexico, between June 2022 and June 2023. The median age of the patients was 29.5 years, 60.9% with severe hemophilia A, 53.6% were under some factor VIII prophylaxis regimen, and 52.4% had home therapy. The median annualized bleeding rate (ABR) was one bleed/year (IQR 0–3 bleeds/year) including a median of zero joint bleeds/year (IQR 0–3 bleeds/year). The presence of high-response inhibitors was detected in 8.5%, with an overall incidence of inhibitors of 14.6% of the cohort. Univariate analysis showed that inhibitors (OR 21.10; CI 95% 1.20–370.3; P = 0.03) and clinical arthropathy (OR 6.14; CI 95% 2.13–17.68; P = 0.001) were significantly higher in severe hemophilia. Clinically significant arthropathy was found in 71.9% of patients. Ultrasonography of the target joints showed that mainly cartilage degeneration was affected. Blood transfusion-associated viral infections were detected in 10.9% of patients. In our HTC, current treatment with hemostatic agents allows adequate control of ABR with acceptable inhibitor rates. However, we still have joint damage in most patients, which is partly explained by the fact that prophylaxis was introduced only in recent years.